Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of MK-0616 Capsules and Tablets in Healthy Participants
NCT06592339Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (6 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to 24 hours and 5 more. Started Oct 2022; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06592339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592339.